Multiple Myeloma in Session: Fellows Journal Club

Capsule Summaries, slidesets, and interactive text modules on multiple myeloma.
Sagar Lonial, MD
Loretta Nastoupil, MD
Claudia E. Paba-Prada, MD
Paul G. Richardson, MD
Ravi Vij, MD
Tzu-Fei Wang, MD

Edition 1

In this CME-certified learning module, Claudia E. Paba-Prada, MD, and Paul G. Richardson, MD, discuss 3 important randomized trials and relevant case examples on topics related to the treatment of patients with multiple myeloma, including the role of bortezomib-containing regimens as induction and consolidation therapy, thalidomide maintenance therapy, and allogeneic stem cell transplantation.

Claudia E. Paba-Prada, MD Paul G. Richardson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: May 11, 2012 Expiration: May 10, 2013

Edition 2

In this CME-certified learning module, Sagar Lonial, MD, and Loretta Nastoupil, MD, discuss 4 important clinical trials and relevant case examples on topics related to the treatment of patients with multiple myeloma, including bortezomib/thalidomide/dexamethasone for disease progression or relapse following autologous stem cell transplantation, elotuzumab/lenalidomide/low-dose dexamethasone for relapsed/refractory disease, lenalidomide maintenance therapy after stem cell transplantation, and carfilzomib for relapsed/refractory disease.

Sagar Lonial, MD Loretta Nastoupil, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 30, 2012 Expiration: July 29, 2013

Edition 3

In this third installment of the Multiple Myeloma Fellows Journal Club, Ravi Vij, MD, and Tzu-Fei Wang, MD, discuss 3 recent studies on the use of carfilzomib, pomalidomide, and elotuzumab for patients with multiple myeloma and present examples of cases that highlight the use of these agents.

Ravi Vij, MD Tzu-Fei Wang, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 18, 2012 Expiration: September 17, 2013

Edition 4

In this fourth installment of the Multiple Myeloma Fellows Journal Club, Sagar Lonial, MD, and Loretta Nastoupil, MD, discuss current risk stratification, new data that improve prognostic accuracy, and the role of imaging with PET/CT. The faculty provide case examples that interactively assess participants' understanding of risk stratification based on clinical findings.

Sagar Lonial, MD Loretta Nastoupil, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 28, 2012 Expiration: November 27, 2013

Journal Article Reviews

Findings suggest survival is prolonged in a group of patients without certain high-risk cytogenetic abnormalities and with a low β2-microglobulin level.

Released: November 27, 2012

Findings suggest survival is prolonged in a group of patients without certain high-risk cytogenetic abnormalities and with a low β2-microglobulin level.

Released: November 27, 2012

In this randomized phase III trial, VTD yielded superior CR/nCR rates, TTP, and PFS compared with TD in newly diagnosed MM patients who received double ASCT.

Released: April 10, 2012

Review key data from a phase III clinical trial that evaluated efficacy and safety of thalidomide/dexamethasone with or without bortezomib when used as induction therapy before and consolidation therapy after double ASCT in patients with newly diagnosed multiple myeloma.

Released: April 16, 2012

Patients receiving bortezomib/thalidomide/dexamethasone experienced a longer median time to progression, improved response, and longer duration of response than those receiving thalidomide/dexamethasone but also experienced a higher incidence of neuropathy.

Released: June 21, 2012

Patients receiving bortezomib/thalidomide/dexamethasone experienced a longer median time to progression, improved response, and longer duration of response than those receiving thalidomide/dexamethasone but also experienced a higher incidence of neuropathy.

Released: July 10, 2012

The combination of carfilzomib, lenalidomide, and low-dose dexamethasone was highly active in newly diagnosed patients and did not provoke significant peripheral neuropathy.

Released: August 22, 2012

Released: August 22, 2012

In patients with relapsed/refractory multiple myeloma, combination of elotuzumab and bortezomib was active and associated with manageable toxicities.

Released: August 22, 2012

Released: August 22, 2012

A comparison of transplantation strategies finds that auto/allo-HSCT yields similar PFS and OS outcomes vs tandem auto-HSCT with or without thalidomide/dexamethasone maintenance therapy.

Released: April 10, 2012

Review key data from a clinical trial comparing two transplantation strategies auto/allo-HSCT vs tandem auto-HSCT in patients with low-risk multiple myeloma.

Released: April 16, 2012

Two doses of pomalidomide examined in this study given in combination with dexamethasone, provided equivalent efficacy in bortezomib and lenalidomide dual-refractory patients.

Released: August 22, 2012

Released: August 22, 2012

Long-term lenalidomide maintenance after ASCT significantly improves PFS and TTP, although with increased toxicity and rates of second primary malignancies.

Released: June 21, 2012

Lenalidomide maintenance is feasible after autologous stem cell transplantation in multiple myeloma patients.

Released: July 11, 2012

In the MRC Myeloma IX trial, maintenance therapy with thalidomide improved PFS and showed a trend toward a late improvement in OS in patients with favorable cytogenetics.

Released: April 10, 2012

Review key data from the phase III MRC Myeloma IX investigation of thalidomide maintenance therapy in multiple myeloma.

Released: April 16, 2012

Assessing bone marrow plasma cell involvement in bone marrow aspirates may support earlier treatment intervention in SMM.

Released: November 27, 2012

Assessing bone marrow plasma cell involvement in bone marrow aspirates may support earlier treatment intervention in SMM.

Released: November 27, 2012

Single-agent carfilzomib is active in a dose-dependent manner and well tolerated with a low risk of peripheral neuropathy in bortezomib-naive patients with relapsed/refractory multiple myeloma.

Released: June 21, 2012

Heavily pretreated patients receiving single agent carfilzomib experienced a high overall response rate with a low rate of peripheral neuropathy.

Released: July 10, 2012

FDG PET/CT was a reliable predictor of 4-year survival rates when used to determine the presence of focal lesions and extramedullary disease and a standardized FDG uptake value at baseline, after thalidomide/dexamethasone induction therapy and double ASCT.

Released: November 27, 2012

FDG PET/CT was a reliable predictor of 4-year survival rates when used to determine the presence of focal lesions and extramedullary disease and a standardized FDG uptake value at baseline, after thalidomide/dexamethasone induction therapy and double ASCT.

Released: November 27, 2012
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
Celgene Corporation
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?